Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2015. The report, dated December 10, 2015, serves as a notification of corporate governance changes rather than a financial results announcement.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document contains no financial performance data.
Material Changes
The primary material change disclosed is a Board Committee appointment:
- Vindi Banga, Senior Independent Director designate and Independent Non-Executive Director, has been appointed to the Audit & Risk, Nominations, and Remuneration Committees.
- This appointment is effective as of January 1, 2016.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on strategy, risks, contingencies, or unusual items. The document is limited to the announcement of the director's committee assignments.
Key Facts for Investor Verification
- Verify the effective date of Vindi Banga's committee appointments (January 1, 2016).
- Confirm the specific committees assigned (Audit & Risk, Nominations, and Remuneration).
- Note that this filing does not contain financial results; investors should refer to the Company's Form 20-F or quarterly reports for financial data.